NCT03749317

Trial to Evaluate the Efficacy and Safety of IVIEW-1201 in Acute Viral Conjunctivitis

A Double-Masked, Placebo-Controlled, Randomized, Phase II Clinical Trial To Assess The Efficacy Of IVIEW-1201 In The Treatment Of Acute Adenoviral Conjunctivitis

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 135 (actual)
• Sponsor: IVIEW Therapeutics Inc. · Industry
• Sex: All
• Age: 15 Years – 70 Years
• Healthy volunteers: Not accepted

Summary

A Phase 2, Multi-center, Randomized, Double-Masked Study to Evaluate the Clinical Efficacy and Safety of IVIEW-1201 (1.0% Povidone-Iodine) Gel Forming Ophthalmic Solution Compared to Placebo in the Treatment of Adenoviral Conjunctivitis

Conditions

• Adenoviral Conjunctivitis

Interventions

Type	Name	Description
DRUG	IVIEW-1201	IVIEW-1201; QID; one drop per eye, four times per day (QID) for 7 days
DRUG	Placebo	Placebo drug; QID; one drop per eye, four times per day (QID) for 7 days

Timeline

• Start date: 2023-02-20
• Primary completion: 2024-04-30
• Completion: 2024-12-31
• First posted: 2018-11-21
• Last updated: 2025-10-15

Locations

1 site across 1 country: India

Regulatory

• FDA-regulated drug study